natgillin/translations-raw huggingface dataset:
It is recommended that a maximum injection volume of 1 mL per injection site, corresponding to a dose of 20 mg of somatropin, should not be exceeded.
Največjega volumna injiciranja 1 ml na mesto injiciranja, kar ustreza odmerku 20 mg somatropina, ni priporočljivo prekoračiti.
Somatropin promotes cellular protein synthesis and nitrogen retention.
Somatropin spodbuja celično sintezo beljakovin in zadrževanje dušika.
Skin and subcutaneous tissue disorders Common: Swelling face, acne, allergic dermatitis, hyperhidrosis, urticaria, rash
Bolezni kože in podkožja pogosti: oteklost obraza, akne, alergijski dermatitis, hiperhidroza, urtikarija, izpuščaj
IGF-I SDS in the range of +1 to +2
SDS IGF-I v razponu +1 do +2
Development of new tumours or reappearance of previously existing tumours has been reported during treatment with growth hormones.
Med zdravljenjem z rastnimi hormoni so poročali o razvoju novih tumorjev ali ponovnem pojavu prej obstoječih tumorjev.
Following repeated weekly subcutaneous administration of a mean dose of 4.4 mg prolonged release somatropin to adults with GHD the Cmax and tmax of plasma hGH were about 4.5 ng/mL and 15 h respectively.
Po ponavljajočem se tedenskem subkutanem dajanju povprečnega odmerka 4,4 mg somatropina s podaljšanim sproščanjem odraslim bolnikom z GHD, je bila Cmax plazemskega hGH približno 4,5 ng/ml in tmax 15 ur.
Injecting the suspension
Injiciranje suspenzije
Somatropin Biopartners has no or negligible effects on the ability to drive and use machines.
Zdravilo Somatropin Biopartners nima vpliva ali ima zanemarljivi vpliv na sposobnost vožnje in upravljanja s stroji.
Uncommon, may affect up to 1 in 100 people - enlargement of the male breast
Občasni; pojavijo se lahko pri največ 1 od 100 bolnikov - povečanje moških prsi
Skin and subcutaneous tissue disorders Common: pigmentation disorder (1.1%)
Bolezni kože in podkožja pogosti: motnje pigmentacije (1,1 %)
Only stop swirling the vial once the suspension appears uniform, white and all the powder on the bottom is dispersed.
Vialo prenehajte vrteti šele ko opazite, da je suspenzija homogena in bela ter se je ves prašek na dnu razpustil.
Rare, may affect up to 1 in 1,000 people - symptoms of increased pressure in the skull such as severe and recurrent headache, visual changes, nausea and/or vomiting
Redki; pojavijo se lahko pri največ 1 od 1.000 bolnikov - simptomi zvišanega tlaka v lobanji, kot so hud in ponavljajoči se glavobol, spremembe vida,
Rare, may affect up to 1 in 100 people - abnormal sensation such as prickling, tingling and itchiness - high blood pressure
Redki; pojavijo se lahko pri največ 1 od 100 bolnikov - nenormalni občutki, kot so ščemenje, zbadanje in srbenje - visok krvni tlak
In patients with an already manifest diabetes mellitus, the anti-diabetic therapy might require adjustment when somatropin treatment is initiated.
Pri bolnikih z že izraženo sladkorno boleznijo utegne zdravljenje s somatropinom na začetku zdravljenja zahtevati prilagoditev odmerka antidiabetičnega zdravila.
Somatropin Biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth hormone deficiency (GHD).
Zdravilo Somatropin Biopartners je indicirano kot nadomestno zdravljenje endogenega rastnega hormona pri odraslih s pomanjkanjem rastnega hormona (GHD, growth hormone deficiency), ki se začne v otroštvu ali odrasli dobi.
previous dose Dose change at a time
Dejanje glede na prejšnji odmerek Posamezna sprememba odmerka
A baseline scan is recommended in these patients before instituting growth hormone replacement therapy.
Pri teh bolnikih se pred uvedbo nadomestnega zdravljenja z rastnim hormonom priporoča osnovna preiskava.
Contact your doctor if this happens.
V tem primeru se posvetujte s svojim zdravnikom.
Shelf-life after reconstitution with solvent
Rok uporabnosti po rekonstituciji z vehiklom
Therefore, in children weighing more than 40 kg the overall injection volume must be divided into equal parts between two injection sites, as more than 1 mL of suspension is required.
Zato morate pri otrocih s telesno maso več kot 40 kg skupni volumen injiciranja razdeliti na dva enaka dela in na dve mesti injiciranja, saj je potrebno več kot 1 ml suspenzije.
The appropriate volume should be withdrawn in a sterile syringe via a sterile 26-gauge needle: The vial should be turned upside down, with the syringe in, and the tip of the needle should be placed in the suspension which is then slowly withdrawn.
S sterilno injekcijsko brizgo z iglo velikosti 26 G izvlecite potrebno količino: vialo obrnite navzdol z vstavljeno injekcijsko brizgo in iglo v suspenziji, ki jo nato počasi izvlecite.
Growth hormone increases the extrathyroidal conversion of thyroxin (T4) to triiodothyronine (T3) and may unmask central hypothyroidism.
Rastni hormon poveča pretvorbo tiroksina (T4) v triiodotironin (T3) zunaj ščitnice in lahko tako razkrije začetni hipotiroidizem.
* Each vial contains an overfill of somatropin powder to allow the withdrawal of the required amount of somatropin when reconstituted (see section 6.6).
* Vsaka viala vsebuje presežek praška somatropina, kar omogoča izvlek potrebne količine rekonstituiranega somatropina (glejte poglavje 6.6).
Common: headache (4.4%), lethargy (1.1%), dizziness (2.6%) Rare: paraesthesia*
Bolezni živčevja pogosti: glavobol (4,4 %), letargičnost (1,1 %), omotica (2,6 %) redki: parestezija*
Investigations Common: decreased blood cortisol (2.2%)
Preiskave pogosti: zmanjšana raven kortizola v krvi (2,2 %) Opis izbranih neželenih učinkov
Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, somatropin and agonists, ATC code: H01AC01
Farmakoterapevtska skupina: hipofizni in hipotalamični hormoni in sorodne učinkovine, hormoni prednjega režnja hipofize in sorodne učinkovine, oznaka ATC: H01AC01
4 vials of 20 mg powder
4 viale z 20 mg praška
Fatty tissue under the skin can shrink at the site of injection on repeated administration at the same site.
Maščobo tkivo pod kožo se lahko na mestu injiciranja skrči, če si zdravilo pogosto injicirate v isto mesto.
Patients receiving concomitant glucocorticoid therapy should have their dose carefully adjusted.
Pri bolnikih, ki se sočasno zdravijo z glukokortikoidi, je treba odmerek skrbno prilagoditi.
Paediatric population (below 2 years of age) Somatropin Biopartners should not be used in infants below the age of 2 years.
Zdravila Somatropin Biopartners ne uporabljajte pri dojenčkih, starih manj kot 2 leti.
4 vials of 10 mg powder
4 viale z 10 mg praška
Paediatric patients with endocrine disorders, including GHD, may develop slipped capital femoral epiphyses more frequently.
Pri pediatričnih bolnikih z motnjami pri delovanju žlez z notranjim izločanjem, tudi z GHD, lahko pogosteje kot pri splošni populaciji zdrsne epifiza stegnenične glavice.
Psychiatric disorders Very rare: insomnia*
Psihiatrične motnje zelo redki: nespečnost*
The powder is white to almost white, the solvent is a clear liquid.
Prašek je bel do belkast, vehikel pa je bistra tekočina.
Excessive glucocorticoid therapy can inhibit the actions of hGH.
Čezmerno zdravljenje z glukokortikoidi lahko zavira učinek hGH.
General disorders and administration site conditions Very common: Oedema peripheral, oedema (local and generalised)* Common: Fatigue, pain, asthenia, face oedema, local swelling, oedema, thirst, malaise, chest pain, increased weight, injection site pain
Splošne težave in spremembe na mestu aplikacije zelo pogosti: periferni edem, edem (lokalni in generaliziran)* pogosti: utrujenost, bolečina, astenija, obrazni edem, lokalna oteklina, edem, žeja, splošno slabo počutje, bolečine v prsnem košu, povečanje telesne mase, bolečina na mestu injiciranja
Vigorously swirl the vial without touching the rubber top with your fingers until the content is completely mixed.
Močno vrtite vialo, dokler ni vsebina povsem premešana, pri tem pa se ne dotikajte gumijastega vrha.
Musculoskeletal and connective tissue disorders Common: arthralgia (1.1%), pain in extremities (5.1%)
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti: artralgija (1,1 %), bolečine v okončinah (5,1 %)
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 12-month controlled comparative clinical study in 178 treatment naïve children with growth failure due to insufficient secretion of endogenous growth hormone and in a dose finding study.
Naslednje neželene učinke so opazili pri zdravljenju z zdravilom Somatropin Biopartners v 12-mesečni kontrolirani primerjalni klinični študiji s 178 otroci, ki se predhodno še niso zdravili, z zaostankom v rasti zaradi nezadostnega izločanja normalnega endogenega rastnega hormona, in v študiji za določanje odmerka.
Somatropin Biopartners is not recommended in women of childbearing potential not using contraception.
Zdravila Somatropin Biopartners ne uporabljajte pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
Female (on oral oestrogen)
Ženske (ki dobivajo peroralni estrogen)
Cardiac disorders Common: Tachycardia, heart rate abnormal/irregular
Srčne bolezni pogosti: tahikardija, nenormalen/nepravilen srčni utrip
Inject the entire contents of the syringe into the vial of powder, holding the syringe against the vial wall.
Celotno vsebino injekcijske brizge injicirajte v vialo s praškom, pri tem pa držite iglo injekcijske brizge ob steno viale.
Following repeated weekly subcutaneous administration of a mean dose of 0.5 mg/kg prolonged release somatropin to prepubertal children with GHD the Cmax and tmax of plasma hGH were about 60.7 ng/mL and 12.0 h respectively.
Po ponavljajočem se tedenskem subkutanem dajanju povprečnega odmerka 0,5 mg/kg somatropina s podaljšanim sproščanjem otrokom pred puberteto s pomanjkanjem rastnega hormona, je bil Cmax plazemskega hGH približno 60,7 ng/ml in tmax 12,0 ur.
The syringe should be filled with the correct volume of the solvent for injection as listed above and the syringe needle withdrawn from the vial subsequently.
Injekcijsko brizgo napolnite s pravilno količino vehikla za injekcijo, kot je navedeno zgoraj, nato pa iglo injekcijske brizge izvlecite iz viale.
- 0.7 mL in a 1 mL graduated syringe for Somatropin Biopartners 10 mg - 1.2 mL in a 2 mL graduated syringe for Somatropin Biopartners 20 mg
- 0,7 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 10 mg - 1,2 ml v 2 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 20 mg
- if you are allergic to somatropin or any of the other ingredients of this medicine (listed in section 6); - if you have cancer; Tell your doctor if you have an active tumour (cancer).
- če ste alergični na somatropin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Put an adhesive plaster on the injection site.
Na mesto injiciranja zalepite obliž.
Leukaemia has been reported in a small number of GHD patients, some of whom have been treated with somatropin.
Pri majhnem številu bolnikov z GHD, zdravljenih s somatropinom, so poročali o levkemiji.
Use immediately, as the suspension may settle if left standing.
Zdravilo takoj uporabite, saj se lahko suspenzija v nasprotnem primeru usede.
Eye disorders Common: Conjunctivitis, visual acuity reduced
Očesne bolezni pogosti: konjunktivitis, zmanjšana ostrina vida
- 0.4 mL in a 1 mL graduated syringe for Somatropin Biopartners 2 mg - 0.6 mL in a 1 mL graduated syringe for Somatropin Biopartners 4 mg - 0.9 mL in a 1 mL graduated syringe for Somatropin Biopartners 7 mg
- 0,4 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 2 mg - 0,6 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 4 mg - 0,9 ml v 1 ml graduirani injekcijski brizgi za zdravilo Somatropin Biopartners 7 mg
If you use more Somatropin Biopartners than you should
Če ste uporabili večji odmerek zdravila Somatropin Biopartners, kot bi smeli
Other medicines and Somatropin Biopartners
Druga zdravila in zdravilo Somatropin Biopartners
Growth hormone increases the extrathyroidal conversion of T4 to T3 which may result in a reduction in serum T4 and an increase in serum T3 concentrations.
Posledica tega je zmanjšanje serumske vrednosti T4 in zvečanje koncentracije T3.
The results showed weekly administered Somatropin Biopartners to be non inferior to daily administered recombinant hGH with respect to the primary endpoint of height velocity after 12 months.
Rezultati so pokazali, da tedensko dajanje zdravila ni bilo slabše kot dnevno dajanje rekombinantnega hGH glede primarnega cilja študije, hitrosti rasti po 12 mesecih.
Somatropin Biopartners 10 mg is sufficient for use in children up to 20 kg bodyweight.
Zdravilo Somatropin Biopartners 10 mg zadošča za uporabo pri otrocih s telesno maso do 20 kg.
In children, Somatropin Biopartners should be administered subcutaneously at a concentration of 20 mg/mL.
Pri otrocih se zdravilo Somatropin Biopartners daje subkutano v koncentraciji 20 mg/ml.
Withdraw the syringe needle from the vial.
Iglo injekcijske brizge izvlecite iz viale.
Remove the needle guard and fill the syringe with a volume of air equal to the required volume of the solvent for injection, making it easier to withdraw the solvent:
Z injekcijske brizge odstranite varovalo in jo napolnite z volumnom zraka, ki je enak količini potrebnega vehikla za injiciranje, da boste lažje izvlekli vehikel:
Gently tap the syringe to remove small air bubbles.
Po injekcijski brizgi nežno potolcite, da odstranite majhne zračne mehurčke.
Somatropin Biopartners 20 mg is sufficient for use in children up to 40 kg bodyweight.
Zdravilo Somatropin Biopartners 20 mg zadošča za uporabo pri otrocih s telesno maso do 40 kg.
Insert the needle through the centre of the rubber stopper of the solvent vial and inject all of the air into the vial.
Iglo vstavite skozi sredino gumijastega zamaška viale z vehiklom ter ves zrak injicirajte v vialo.
IGF-I SDS in the range of -1 to +1 and more than 1 SDS increase from Baseline Maintain
SDS IGF-I v razponu -1 do +1 in več kot 1 SDS povečanje od izhodišča brez
Common: Paraesthesia, hypoaesthesia, carpal tunnel syndrome, dizziness, somnolence Rare: Benign intracranial hypertension*
Bolezni živčevja zelo pogosti: glavobol pogosti: parestezija, hipestezija, sindrom karpalnega kanala, omotica, zaspanost redki: benigna intrakranialna hipertenzija*
Turn the vial upside down, with the syringe in and place the tip of the needle in the suspension as shown in figure 9.
Vialo obrnite navzdol z injekcijsko brizgo v njej in konico igle potisnite v suspenzijo, kot prikazuje slika 9.
Common: Back pain, pain in extremities, arthralgia, shoulder pain, musculoskeletal stiffness, bone pain, muscular weakness, sensation of heaviness, tendonitis, joint swelling, arthritis, musculosceletal pain, myalgia*
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti: bolečine v hrbtu, bolečine v okončinah, artralgija, bolečine v ramenih, mišično-skeletna togost, bolečine v kosteh, mišična šibkost, občutek teže, tendonitis, oteklost sklepov, artritis, mišičnoskeletna bolečina, mialgija*
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom, farmacevtom ali medicinsko sestro.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for Somatropin Biopartners
IME ZDRAVILA IN POT(I) UPORABE vehikel za zdravilo Somatropin Biopartners
Reproductive system and breast disorders Very rare: gynaecomastia*
Motnje reprodukcije in dojk zelo redki: ginekomastija*
Important information about some of the ingredients of Somatropin Biopartners
Pomembne informacije o nekaterih sestavinah zdravila Somatropin Biopartners
QUALITATIVE AND QUANTITATIVE COMPOSITION One vial delivers 20 mg of somatropin* (corresponding to 60 IU) After reconstitution, 1 mL of suspension contains 20 mg somatropin (20 mg/mL).
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala dostavi 20 mg somatropina* (kar ustreza 60 i.e.) Po rekonstituciji 1 ml suspenzije vsebuje 20 mg somatropina (20 mg/ml).
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 6-month controlled clinical study with 151 adult patients with GHD of adult or childhood-onset and in a 6-month extension study.
Naslednje neželene učinke so opazili pri zdravljenju z zdravilom Somatropin Biopartners v 6-mesečni kontrolirani klinični študiji s 151 odraslimi bolniki s pomanjkanjem rastnega hormona z začetkom v odrasli dobi ali v otroštvu, in v 6-mesečnem podaljšku študije.
Common: Adrenal insufficiency, decreased free thyroxine, decreased free tri-iodothyronine, increased blood TSH, hypothyroidism*
Bolezni endokrinega sistema pogosti: adrenalna insuficienca, zmanjšanje vrednosti prostega tiroksina, zmanjšanje vrednosti prostega trijodtironina, povečanje vrednosti TSH v krvi, hipotiroidizem*
After preparation, the product must be used immediately.
Pripravljeno zdravilo je treba uporabiti takoj.
Tumours must be inactive and cancer therapy complete before you can start your treatment with growth hormone.
Tumorji morajo biti neaktivni, preden začnete zdravljenje z rastnim hormonom, pa morate zaključiti zdravljenje tumorja.
Do not use Somatropin Biopartners
Ne uporabljajte zdravila Somatropin Biopartners
The amino acid sequence of the active substance is identical to that of hGH of pituitary origin.
Aminokislinsko zaporedje zdravilne učinkovine je identično aminokislinskemu zaporedju hGH hipofiznega izvora.
Investigations Common: Increased blood phosphorus, increased or decreased IGF
Preiskave pogosti: povečana raven fosforja v krvi, povečana ali zmanjšana raven insulinu podobnega rastnega dejavnika
The syringe should be filled with a volume of air equal to the required volume of the solvent for injection and the air injected into the solvent vial to make it easier to withdraw the solvent.
Injekcijsko brizgo napolnite z volumnom zraka, ki je enak količini potrebnega vehikla za injiciranje, in zrak injicirajte v vialo z vehiklom za lažji izvlek vehikla.
Powder and solvent for prolonged-release suspension for injection 20 mg powder in a vial and 1.5 mL solvent in a vial 1 vial of 20 mg powder
Vehikel: srednjeverižni trigliceridi prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem 20 mg prašek v viali in 1,5 ml vehikla v viali 1 viala z 20 mg praška
Use a 1 mL or 2 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial.
Uporabite 1 ml ali 2 ml graduirano injekcijsko brizgo z iglo velikosti 19 G ali večjo, da izvlečete vehikel iz viale.
Hold the syringe upright.
Injekcijsko brizgo držite navpik.
The other ingredients are sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous.
Druge sestavine zdravila so natrijev hialuronat, jajčni fosfolipidi, brezvodni natrijev dihidrogenfosfat in brezvodni dinatrijev fosfat.
Common, may affect up to 1 in 10 people - tiredness or weight gain due to underactive thyroid gland - reduced function of the adrenal gland (which may show as tiredness) - mild blood sugar increase - headache, lethargy (lack of energy), dizziness - vomiting, stomach ache - discoloration of the skin - pain in joints, arms or legs - pain, discoloration, swelling, hardening, reddening or feeling of warmth at the injection site - tissue swelling - fever - changes in blood levels of certain hormones
Pogosti; pojavijo se lahko pri največ 1 od 10 bolnikov - utrujenost ali pridobivanje telesne mase zaradi premalo aktivne ščitnice - zmanjšano delovanje nadledvične žleze (kar se kaže kot utrujenost) - blago povečanje krvnega sladkorja - glavobol, letargičnost (pomanjkanje energije), omotica - bruhanje, bolečine v trebuhu - obarvanje kože - bolečine v sklepih, rokah ali nogah - bolečina, obarvanje, oteklina, otrdlina, rdečina ali občutek vročine na mestu injiciranja - oteklina tkiva - povečana telesna temperatura - spremenjeni ravni nekaterih hormonov v krvi
Somatropin Biopartners is indicated in children and adolescents aged 2 to 18 years for long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone.
Zdravilo Somatropin Biopartners je indicirano pri otrocih in mladostnikih, starih od 2 do 18 let, z zaostankom v rasti zaradi nezadostnega izločanja normalnega endogenega rastnega hormona.
Turn the vial upside down, with the syringe inside and place the tip of the needle in the solvent as seen in figure 5.
Vialo obrnite navzdol z injekcijsko brizgo v njej in konico igle potisnite v vehikel, kot prikazuje slika 5.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Common: Neoplasm progression (1 case of neoplasm progression in a female patient with a history of neurofibromatosis and radiation treatment), acrochordon, craniopharyngioma
pogosti: napredovanje novotvorbe (1 primer napredovanja novotvorbe pri bolnici z anamnezo nevrofibromatoze in zdravljenja z obsevanjem), akrohordon, kraniofaringiom
Hypothyroidism may develop in patients with central subclinical hypothyroidism after initiating therapy with growth hormone.
Pri bolnikih s centralnim subkliničnim hipotiroidizmom se lahko pri uvedbi zdravljenja z rastnim hormonom pojavi hipotiroidizem.
IGF-I SDS in the range of -1 to +1 and less than 1SDS increase from Baseline
SDS IGF-I v razponu -1 do +1 in manj kot 1 SDS povečanje od izhodišča povečanje
Holding the needle against the inside vial wall, the entire contents of the syringe should be injected into the powder vial.
Iglo držite na notranjo steno viale in v vialo s praškom injicirajte celotno vsebino injekcijske brizge.
There is no antidote for somatropin overdose.
Za preveliki odmerek somatropina ni znanega antidota.
Animal studies are insufficient with respect to reproductive toxicity (see section
Ni dovolj študij na živalih o vplivu zdravila na sposobnost razmnoževanja (glejte poglavje 5.3).
If you stop using Somatropin Biopartners
Če ste prenehali uporabljati zdravilo Somatropin Biopartners
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Cases of malignant and benign tumour recurrences, de-novo and secondary tumours have been reported in temporal relationship with somatropin therapy.
V časovnem razmerju z zdravljenjem s somatropinom so poročali o primerih ponovnih pojavov malignih in benignih tumorjev, na novo nastalih tumorjev in sekundarnih tumorjev.
The plunger should be pushed up gently, until all bubbles are removed from the syringe and needle.
Bat nežno potiskajte, dokler ne odstranite vseh mehurčkov iz injekcijske brizge in igle.
The 20-mg vial contains an overfill of somatropin powder to allow the withdrawal of up to 20 mg (1 mL suspension) of somatropin when reconstituted.
20-mg viala vsebuje presežek praška somatropina, kar omogoči odvzem do 20 mg (1 ml suspenzije) rekonstituiranega somatropina.
Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 4 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection
Somatropin Biopartners 2 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Somatropin Biopartners 4 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Somatropin Biopartners 7 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem za odrasle
Somatropin Biopartners should be administered subcutaneously at a concentration of 10 mg/mL.
Zdravilo Somatropin Biopartners se daje subkutano v koncentraciji 10 mg/ml.